IgA Nephropathy Pipeline Advancements Report 2025: DelveInsight Highlights Emerging Therapeutics Reshaping the Treatment Landscape

DelveInsight's "IgA Nephropathy Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the IgA Nephropathy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the IgA Nephropathy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the IgA Nephropathy Pipeline? Click here to explore the therapies and trials making headlines @ IgA Nephropathy Pipeline Outlook Report [https://www.delveinsight.com/sample-request/iga-nephropathy-igan-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the IgA Nephropathy Pipeline Report

* On November 26, 2025, Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Voyxact (sibeprenlimab-szsi) for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. Voyxact, a self-administered subcutaneous injection administered every four weeks, received this designation based on the interim analysis of the VISIONARY Phase 3 trial, which demonstrated a statistically significant, placebo-adjusted 51% reduction in proteinuria at nine months of treatment (50% with Voyxact vs. 2% with placebo; P



This release was published on openPR.